REECUR

NCT03416517 📎

Regimen

Experimental
Three experimental arms — irinotecan+temozolomide (IT), gemcitabine+docetaxel (GD), ifosfamide high-dose (IFOS) — vs topotecan+cyclophosphamide (TC)
Control
Topotecan + cyclophosphamide (TC, the prior reference)

Population

First recurrence / primary refractory Ewing sarcoma, age 4-50

Key finding

First ever randomized relapsed-Ewing trial. High-dose ifosfamide emerged as the new reference standard. Full primary publication not yet indexed in PubMed at time of writing — PMID to verify once the Lancet Oncology / NEJM paper is released. VIT regimen NOT directly in this trial but IT arm informative.

Guideline citations

  • NCCN BONE (p.32)